Gene-expression analysis of adult-onset Still's disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity

Pediatric Rheumatology

Volumn 13, Issue 1, 2015, Pages

  Nirmala, Nanguneri ^a   Brachat, Arndt ^b   Feist, Eugen ^c   Blank, Norbert ^d   Specker, Christof ^e   Witt, Matthias ^f   Zernicke, Jan ^c   Martini, Alberto ^g   Junge, Guido ^b  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

^f UNIVERSITY OF MUNICH   (Germany)

^g UNIVERSITY OF GENOA   (Italy)

Author keywords

Adult onset Still's disease; Canakinumab; Gene expression; Interleukin 1 ; Systemic juvenile idiopathic arthritis

Indexed keywords

CANAKINUMAB; INTERLEUKIN 1BETA; MONOCLONAL ANTIBODY;

ADULT; ADULT ONSET STILL DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENETIC ASSOCIATION; HUMAN; MALE; NEUTROPHIL COUNT; PHENOTYPE; PRIORITY JOURNAL; SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS; TREATMENT RESPONSE; UPREGULATION; ANTAGONISTS AND INHIBITORS; CASE CONTROL STUDY; CHILD; CLINICAL TRIAL; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENETICS; JUVENILE RHEUMATOID ARTHRITIS;

ADULT; ANTIBODIES, MONOCLONAL; ARTHRITIS, JUVENILE; CASE-CONTROL STUDIES; CHILD; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; INTERLEUKIN-1BETA; MALE; STILL'S DISEASE, ADULT-ONSET;

EID: 84947559405     PISSN: None     EISSN: 15460096     Source Type: Journal    
DOI: 10.1186/s12969-015-0047-3     Document Type: Article

References (27)

1. Jamilloux Y, Gerfaud-Ventin M, Martinon F, Belot A, Henry T, Sève P. Pathogenesis of adult-onset Still's disease: new insights from the juvenile counterpart. Immunol Res. 2015;61:53-62.
2. Martini A. It is time to rethink juvenile idiopathic arthritis classification and nomenclature. Ann Rheum Dis. 2012;71:1437-9.
3. Fautrel B. Adult-onset Still disease. Best Pract Res Clin Rheumatol. 2008;22:773-92.
4. Luthi F, Zufferey P, Hofer MF, So AK. "Adolescent-onset Still's disease": characteristics and outcome in comparison with adult-onset Still's disease. Clin Exp Rheumatol. 2002;20:427-30.
5. Uppal SS, Pande IR, Kumar A, Kailash S, Sekharan NG, Adya CM, et al. Adult onset Still's disease in northern India: comparison with juvenile onset Still's disease. Br J Rheumatol. 1995;34:429-34.
6. Still GF. On a form of chronic joint disease in children. Med Chir Trans. 1897;80:47-60.9.
7. Frosch M, Metze D, Foell D, Vogl T, Sorg C, Sunderkötter C, et al. Early activation of cutaneous vessels and epithelial cells is characteristic of acute systemic onset juvenile idiopathic arthritis. Exp Dermatol. 2005;14:259-65.
8. Kim HA, An JM, Nam JY, Jeon JY, Suh CH. Serum S100A8/A9, but not follistatin-like protein 1 and interleukin 18, may be a useful biomarker of disease activity in adult-onset Still's disease. J Rheumatol. 2012;39:1399-406.
9. Chen D-Y, Chen Y-M, Lan J-L, Lin C-C, Chen H-H. Potential role of TH17 cells in the pathogenesis of adult-onset Still's disease. Rheumatology. 2010;49:2305-12.
10. Kötter I, Wacker A, Koch S, Henes J, Richter C, Engel A, et al. Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature. Semin Arthritis Rheum. 2007;37:189-97.
11. Avau A, Put K, Wouters CH, Matthys P. Cytokine balance and cytokine-driven natural killer cell dysfunction in systemic juvenile idiopathic arthritis. Cytokine Growth Factor Rev. 2015;26:35-45.
12. Félix FH, Leal LK, Fontenele JB. Cloak and dagger: the case for adult onset still disease and hemophagocytic lymphohistiocytosis. Rheumatol Int. 2009;29:973-4.
13. Ravelli A, Grom AA, Behrens EM, Cron RQ. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun. 2012;13:289-98.
14. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. 2005;201:1479-86.
15. Fall N, Barnes M, Thornton S, Luyrink L, Olson J, Ilowite NT, et al. Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum. 2007;56:3793-804.
16. Ruperto N, Quartier P, Wulffraat N, Woo P, Ravelli A, Mouy R, et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum. 2012;64:557-67.
17. Ruperto N, Brunner HI, Quartier P, Constantin T, Wulfraat N, Horneff G, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2396-406.
18. Kontzias A, Efthimiou P. The use of Canakinumab, a novel IL-1β long-acting inhibitor, in refractory adult-onset Still's disease. Semin Arthritis Rheum. 2012;42:201-5.
19. Laskari K, Tzioufas AG, Moutsopoulos HM. Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study. Arthritis Res Ther. 2011;13:R91.
20. Efthimiou P, Kontzias A, Ward CM, Ogden NS. Adult-onset Still's disease: can recent advances in our understanding of its pathogenesis lead to targeted therapy? Nat Clin Pract Rheumatol. 2007;3:328-35.
21. Fitzgerald AA, Leclercq SA, Yan A, Hornik JE, Dinarello CA. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum. 2005;52:1794-803.
22. Petryna O, Cush JJ, Efthimiou P. IL-1 Trap rilonacept in refractory adult onset Still's disease. Ann Rheum Dis. 2012;71:2056-7.
23. Nordström D, Knight A, Luukkainen R, van Vollenhaven R, Rantalaiho V, Kajalainen A, et al. Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study. J Rheumatol. 2012;39:2008-11.
24. Naumann L, Feist E, Natusch A, Langen S, Krause A, Buttgereit F, et al. IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease. Ann Rheum Dis. 2010;69:466-7.
25. Brachat A, Grom A, Wulffraat N, Brunner H, Quartier P, Brik R, et al. Changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy. Ann Rheum Dis. 2014;73(Suppl2):62.
26. ClinicalTrials.gov. NCT02204293. https://clinicaltrials.gov/ct2/show/NCT02204293. Accessed November 18, 2015.
27. Wu D, Lim E, Vaillant F, Asselin-Labat ML, Visvader JE, Smyth GK. ROAST: rotation gene set tests for complex microarray experiments. Bioinformatics. 2010;26:2176-82.